Skip to content
Screener

Prime Medicine PRME EPS (Diluted)

EPS (Diluted) at other companies

Eli Lilly logo
Eli LillyLLY
$7.94+26.2%
Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
$4.31+8.0%
Intellia Therapeutics logo
Intellia TherapeuticsNTLA
-$0.80+18.4%
CRISPR Therapeutics logo
CRISPR TherapeuticsCRSP
-$1.28+19.0%
Beam Therapeutics logo
Beam TherapeuticsBEAM
-$0.91+26.0%
Regenxbio logo
RegenxbioRGNX
$0.43+131%

Other financials

Income statement

See full
Revenue$838.0K-61.6%
Operating income-$43.3M+18.9%
Net income-$42.1M+19.9%

Balance sheet

See full
Cash & equivalents$61.1M-9.4%
Total debt$112.5M-6.1%
Total equity$39.8M-34.6%
Total assets$249.0M-10.7%

Cash flow

See full
Operating cash flow-$41.0M+0.9%
CapEx$46.0K-97.1%
Free cash flow-$41.1M+4.4%

Valuation

See full
Market cap$558.64M-10.7%
Enterprise value$609.98M-10.0%

Profitability

See full
Operating margin-4,498.1%-1,134pp
Net margin-4,342.4%-1,099pp
FCF margin-3,607.4%

Returns & leverage

See full
Return on equity-373.3%-1,281pp
Debt / equity2.8×+0.9×
Current ratio3.1×-0.5×

Where this comes from

Reported directly by Prime Medicine in its filing.

Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.

The source filing: Prime Medicine’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 8:03 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001628280-26-053883
(in thousands, except share and per share amounts)Three Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Other income, net551810655
Total other income, net1,1767862,7081,288
Net loss attributable to common stockholders$(42,109)$(52,591)$(91,231)$(104,481)
Net loss per share attributable to common stockholders, basic and diluted$(0.24)$(0.41)$(0.51)$(0.81)
Weighted-average common shares outstanding, basic and diluted177,224,892129,185,918177,160,914128,439,349
Comprehensive loss:
Net loss$(42,109)$(52,591)$(91,231)$(104,481)
Change in unrealized (loss) income on investments, net of tax(8)5(91)(11)

Item 1. Financial Statements (unaudited)

FAQ

What is Prime Medicine's EPS (diluted)?
Prime Medicine (PRME) reported EPS (diluted) of -$0.24 in Q2 2026.
How has Prime Medicine's EPS (diluted) changed year-over-year?
Prime Medicine's EPS (diluted) increased by 41.5% year-over-year, from -$0.41 to -$0.24.
What is the long-term trend for Prime Medicine's EPS (diluted)?
Over 2 years (2023 to 2025), Prime Medicine's EPS (diluted) has grown at a -20.7% compound annual growth rate (CAGR), from -$2.18 to -$1.37.
What does EPS (diluted) mean?
Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.

Ask your AI about Prime Medicine's eps (diluted).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude